Mustang Bio axes 81% of staffers: The CAR-T cell therapy company plans to implement a workforce reduction throughout April to preserve cash in the second quarter. Mustang had 80 full-time employees as of the end of 2023, per an SEC filing. — Ayisha Sharma
MaaT Pharma details data for microbiome therapy: The company’s lead candidate had 42% overall survival after 18 months in a study with 140 patients with acute graft versus host disease (aGvHD), demonstrating a “high and durable response rate.” Another Phase 3 trial evaluating the drug in corticosteroid and ruxolitinib-refractory aGvHD is ongoing. — Katherine Lewin
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.